ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study
December 17, 2021Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123... -
Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S.
March 11, 2021Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 in the United States.
Pharma Sources Insight January 2025
